Acarix - Hearing the beat of 2018
Acarix has laid the groundwork in 2017 for sales development in 2018. The main subset of the key Dan-NICAD study was published in November 2017 and should boost medical awareness. As initial sales were slower than expected, sales forecasts have been adjusted although, with only two quarters’ sales data, these will be revised regularly. Good sales growth in Europe is expected from 2019. With no US trial announced our expected launch date is moved to 2022 from 2021. The indicative value is now SEK448m (formerly SEK728m), implying a fair value of SEK19.46/share (formerly SEK31.62/share). A new CEO will be appointed in 2018.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.